4.7 Article

Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting

Journal

JAMA NETWORK OPEN
Volume 3, Issue 12, Pages -

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/jamanetworkopen.2020.29676

Keywords

-

Funding

  1. National Institute on Drug Abuse, NIH [P30DA040500, R01DA046527]

Ask authors/readers for more resources

Importance Whereas outpatient treatment with medication for opioid use disorder (MOUD) is evidence based, there is a large network of inpatient facilities in the US that are reimbursed by commercial insurers and do not typically offer MOUD. Objective To compare the rates of opioid-related overdose and all-cause hospitalization after outpatient MOUD treatment vs inpatient care. Design, Setting, and Participants This comparative effectiveness research study used deidentified claims of commercially insured individuals in the US from the MarketScan Commercial Claims and Encounters Database from January 1, 2010, to December 31, 2017, to obtain a sample of 37 090 individuals with opioid use disorder who initiated treatment with inpatient care and/or MOUD. Data were analyzed from October 1, 2019, to May 1, 2020. To address nonrandom treatment assignment, individuals with opioid use disorder who initiated MOUD or who entered inpatient care were matched 1:1 based on propensity scores. Exposures The independent variable of interest was the type of treatment initiated. Individuals could initiate 1 of 5 potential treatments: (1) outpatient MOUD, (2) short-term inpatient care, (3) short-term inpatient care followed by outpatient MOUD within 30 days, (4) long-term inpatient care, or (5) long-term inpatient care followed by outpatient MOUD within 30 days. Main Outcomes and Measures Opioid-related overdose and all-cause hospitalization at any point within the 12 months after treatment of opioid use disorder. The hazard for each outcome was estimated using a time-to-event Cox proportional hazards regression model. Results The cohort included 37 090 individuals matched 1:1 between inpatient and outpatient treatment (20 723 [56%] were younger than 30 years; 23 250 [63%] were male). After propensity score matching, compared with the inpatient treatments, initiation of outpatient MOUD alone was followed by the lowest 1-year overdose rate (2.2 [95% CI, 2.0-2.5] per 100 person-years vs 3.5 [95% CI, 2.7-4.4] to 7.0 [95% CI, 4.6-10.7] per 100 person-years) and hospitalization rate (39 [95% CI, 38-40] per 100 person-years vs 57 [95% CI, 54-61] to 74 [95% CI, 73-76] per 100 person-years). Outpatient MOUD was also associated with the lowest hazard of these events compared with inpatient care, which had hazard ratios ranging from 1.71 (95% CI, 1.35-2.17) to 2.67 (95% CI, 1.68-4.23) for overdose and 1.33 (95% CI, 1.23-1.44) to 1.90 (95% CI, 1.83-1.97) for hospitalizations. Conclusions and Relevance The results of this comparative effectiveness research study suggest that lower rates of subsequent overdose and hospitalization are associated with outpatient MOUD compared with short- or long-term inpatient care. When patients and clinicians have a choice of treatment, outpatient MOUD treatment may be associated with lower overdose and hospitalization on balance. Future research should assess which patients benefit most from inpatient care and how best to leverage existing inpatient treatment infrastructure. This comparative effectiveness research study uses 2010-2017 data from the MarketScan Commercial Claims and Encounters Database to compare the rates of opioid-related overdose and all-cause hospitalization after treatment of opioid use disorder in outpatient vs inpatient care settings. Question Do the rates of overdose and hospitalization differ after outpatient medication treatment or inpatient care for opioid use disorder? Findings In this comparative effectiveness research study of 37 090 propensity score-matched individuals with opioid use disorder receiving outpatient medication treatment or inpatient care, all forms of inpatient care (short or long term) were associated with higher risk of subsequent overdose and hospitalization. Meaning The findings suggest that outpatient medication may be less likely than inpatient care to be associated with subsequent overdose or hospitalization.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Substance Abuse

Community-based naloxone coverage equity for the prevention of opioid overdose fatalities in racial/ethnic minority communities in Massachusetts and Rhode Island

Shayla Nolen, Xiao Zang, Avik Chatterjee, Czarina N. Behrends, Traci C. Green, Aranshi Kumar, Benjamin P. Linas, Jake R. Morgan, Sean M. Murphy, Alexander Y. Walley, Shapei Yan, Bruce R. Schackman, Brandon D. L. Marshall

Summary: The study found no racial/ethnic inequities in naloxone distribution at the municipal level in Rhode Island and Massachusetts, USA. Naloxone coverage ratios did not vary significantly among municipalities with different percentages of non-white residents in the multivariable analysis. However, a secondary analysis revealed that municipalities with higher percentages of African American/black residents had higher naloxone coverage ratios.

ADDICTION (2022)

Article Substance Abuse

Broadening access to naloxone: Community predictors of standing order naloxone distribution in Massachusetts

Avik Chatterjee, Shapei Yan, Ziming Xuan, Katherine M. Waye, Audrey M. Lambert, Traci C. Green, Thomas J. Stopka, Robin A. Pollini, Jake R. Morgan, Alexander Y. Walley

Summary: The study found that the quantity and coverage of naloxone dispensed under NSO increased annually, but communities with higher percentages of Hispanic populations and rural characteristics were less likely to dispense naloxone under NSO.

DRUG AND ALCOHOL DEPENDENCE (2022)

Article Health Care Sciences & Services

Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design

Jake R. Morgan, Emily K. Quinn, Christine E. Chaisson, Elizabeth Ciemins, Nikita Stempniewicz, Laura F. White, Benjamin P. Linas, Alexander Y. Walley, Marc R. LaRochelle

Summary: This study aims to investigate the association between individuals with opioid use disorder and the cost-sharing for medication, and the results show that only the medical services deductible is associated with MOUD initiation.

MEDICAL CARE (2022)

Article Substance Abuse

Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis

Alexandra Savinkina, Rajapaksha W. M. A. Madushani, Golnaz Eftekhari Yazdi, Jianing Wang, Joshua A. Barocas, Jake R. Morgan, Sabrina A. Assoumou, Alexander Y. Walley, Benjamin P. Linas, Sean M. Murphy

Summary: Initiating medications for opioid use disorder and implementing linkage policies among detox patients in Massachusetts can effectively prevent fatal opioid overdoses and are cost-effective.

ADDICTION (2022)

Article Gastroenterology & Hepatology

Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral-based treatment regimens: Evidence from a global data set

Jake R. Morgan, Elizabeth Marsh, Alexandra Savinkina, Sonjelle Shilton, Shaun Shadaker, Tengiz Tsertsvadze, George Kamkamidze, Maia Alkhazashvili, Timothy Morgan, Pam Belperio, Lisa Backus, Waheed Doss, Gamal Esmat, Mohamed Hassany, Aisha Elsharkawy, Wafaa Elakel, Mai Mehrez, Graham R. Foster, Constance Wose Kinge, Kara W. Chew, Charles S. Chasela, Ian M. Sanne, Yin M. Thanung, Anne Loarec, Khawar Aslam, Suna Balkan, Philippa J. Easterbrook, Benjamin P. Linas

Summary: To achieve global elimination of hepatitis C virus, scaling up testing is necessary. Point-of-care HCV viral load assays can facilitate testing in hard-to-reach or marginalized populations. This study aimed to determine an acceptable lower limit of detection (LLoD) for detectable HCV viremia as a test for cure. Data from multiple countries and clinical trial registries were analyzed, and it was found that an assay with a detection level of 1000 IU/mL or higher may miss some patients with low-level treatment failure.

JOURNAL OF VIRAL HEPATITIS (2022)

Article Medicine, Research & Experimental

The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for Hepatitis C (Hep C) Screening Trial: rationale and design of a multi-center pragmatic randomized clinical trial of hepatitis C screening in emergency departments

Jason S. Haukoos, Sarah E. Rowan, James W. Galbraith, Richard E. Rothman, Yu-Hsiang Hsieh, Emily Hopkins, Rachel A. Houk, Matthew F. Toerper, Kevin F. Kamis, Jake R. Morgan, Benjamin P. Linas, Alia A. Al-Tayyib, Edward M. Gardner, Michael S. Lyons, Allison L. Sabel, Douglas A. E. White, David L. Wyles

Summary: This article describes a trial that aims to evaluate the comparative effectiveness of non-targeted and targeted HCV screening in emergency departments. The trial will be conducted in three ED centers and will include observational studies to assess cost effectiveness, disparities, and social determinants of health in screening, linkage-to-care, and treatment for HCV.

TRIALS (2022)

Article Public, Environmental & Occupational Health

Estimating Absenteeism Related to Nonalcohol Substance Use in a US National Cohort of Full-Time Employees

Jake R. Morgan, Sean M. Murphy, Sabrina A. Assoumou, Benjamin P. Linas

Summary: This study aimed to estimate absenteeism due to substance use disorder among full-time employees. The results showed a positive association between substance use and absenteeism, highlighting the importance for employers to promote treatment programs for employees in order to reduce the costs associated with absenteeism and turnover.

JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE (2022)

Article Medicine, General & Internal

Prevalence of HIV Preexposure Prophylaxis Prescribing Among Persons With Commercial Insurance and Likely Injection Drug Use

Carl G. Streed, Jake R. Morgan, Mam Jarra Gai, Marc R. Larochelle, Michael K. Paasche-Orlow, Jessica L. Taylor

Summary: This study aimed to estimate the uptake of HIV preexposure prophylaxis (PrEP) among commercially insured individuals with opioid or stimulant use disorder, based on injection drug use (IDU) status. The results showed that HIV PrEP delivery remained low and should be offered alongside substance use disorder treatment and other HIV prevention services.

JAMA NETWORK OPEN (2022)

Article Oncology

Underscreening, overscreening, and guideline-adherent cervical cancer screening in a national cohort

Yeon Woo Lee, Jake R. Morgan, Stephen Fiascone, Rebecca B. Perkins

Summary: This study investigated rates of under- and overscreening for cervical cancer in a national cohort. The results showed that only 18.1% of women received guideline-adherent screening, and 25.4% were unscreened during the 6-year period. Younger women were more likely to be overscreened, while older women were more likely to be underscreened or unscreened. Additional strategies are needed to improve guideline-adherent care for cervical cancer screening.

GYNECOLOGIC ONCOLOGY (2022)

Article Substance Abuse

Evaluating equity in community-based naloxone access among racial/ethnic groups in Massachusetts

Shayla Nolen, Xiao Zang, Avik Chatterjee, Czarina N. Behrends, Traci C. Green, Benjamin P. Linas, Jake R. Morgan, Sean M. Murphy, Alexander Y. Walley, Bruce R. Schackman, Brandon D. L. Marshall

Summary: This study reveals racial/ethnic inequities in the access to naloxone in Massachusetts, with minority groups having lower distribution rates compared to white residents. Moreover, naloxone distribution is more likely to occur in racially segregated communities.

DRUG AND ALCOHOL DEPENDENCE (2022)

Article Substance Abuse

Changes to opioid overdose deaths and community naloxone access among Black, Hispanic and White people from 2016 to 2021 with the onset of the COVID-19 pandemic: An interrupted time-series analysis in Massachusetts, USA

Xiao Zang, Alexander Y. Walley, Avik Chatterjee, Simeon D. Kimmel, Jake R. Morgan, Sean M. Murphy, Benjamin P. Linas, Shayla Nolen, Brittni Reilly, Catherine Urquhart, Bruce R. Schackman, Brandon D. L. Marshall

Summary: The COVID-19 pandemic has led to a significant increase in opioid overdose deaths in Massachusetts, particularly among racial and ethnic minority communities. We compared the impact of the pandemic on opioid overdose fatalities and naloxone distribution across different racial and ethnic groups in the state.

ADDICTION (2023)

Article Health Care Sciences & Services

Comparison of a national commercial pharmacy naloxone data source to state and city pharmacy naloxone data sources-Rhode Island, Massachusetts, and New York City, 2013-2019

Avik Chatterjee, Shapei Yan, Audrey Lambert, Jake R. Morgan, Traci C. Green, Philip J. Jeng, Ali Jalali, Ziming Xuan, Maxwell Krieger, Brandon D. L. Marshall, Alexander Y. Walley, Sean M. Murphy

Summary: This study compared different datasets with the commercially available pharmacy national claims dataset in Massachusetts, Rhode Island, and New York City. The results showed that Symphony's data exceeded the local datasets, except in Rhode Island after legislation required reporting to PDMP.

HEALTH SERVICES RESEARCH (2023)

Meeting Abstract Substance Abuse

Trends in Adult ADHD Diagnosis and Treatment in Patients with Opioid Use Disorder in the United States

Tae Woo Park, Tithi Baul, Jake Morgan, Timothy Wilens, Amy Yule

AMERICAN JOURNAL ON ADDICTIONS (2022)

No Data Available